.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,234,956

« Back to Dashboard

Details for Patent: 5,234,956

Title: Method of preventing NMDA receptor complex-mediated neuronal damage
Abstract:Disclosed is a method for reducing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal a nitric-oxide generating compound, or a physiologically acceptable salt thereof, in a concentration effective to cause such reduction. Also disclosed is a method for reducing NMDA receptor-mediated neuronal damage in a mammal by administering to the mammal nitroprusside, nitroglycerin, or a derivative of one of those compounds, in a concentration effective to cause such reduction.
Inventor(s): Lipton; Stuart A. (Newton, MA)
Assignee: The Children's Medical Center Corporation (Boston, MA)
Filing Date:Sep 22, 1992
Application Number:07/949,342
Claims:1. A method for reducing NMDA receptor-mediated neuronal damage in a human comprising reducing the NMDA-mediated increase in the intraneuronal concentration by administering to said human a compound selected from the group consisting of: a) nitroprusside, b) nitroglycerin, c) an NO-generating derivative of nitroprusside or nitroglycerin, or d) a physiologically acceptable salt of a)-c), above, in a concentration effective to cause such reduction.

2. The method of claim 1, wherein said compound is nitroprusside or a physiologically acceptable salt thereof.

3. The method of claim 1, wherein said compound is nitroglycerine or a physiologically acceptable salt thereof.

4. The method of claim 1, wherein said compound is nitroprusside or an NO-generating derivative thereof.

5. The method of claim 1, wherein said compound is nitroglycerin or an NO-generating derivative thereof.

6. The method of any of claims 1-5, wherein said human is infected with a human immunodeficiency virus.

7. The method of claim 6, wherein said human manifests symptoms of the AIDS related complex or acquired immunodeficiency syndrome.

8. The method of any of claims 1-5 wherein said human suffers from a disorder selected from the group consisting of hypoxia, ischemia, trauma, hypoglycemia, seizures, stroke, Alzheimer's disease, Huntington's disease, or Parkinson's disease.

9. A method for controlling neuronal damage associated with a disorder selected from the group consisting of hypoxia, ischemia, trauma, hypoglycemia, seizures, stroke, Alzheimer's disease, Huntington's disease, Parkinson's disease, and infection with Human Immunodeficiency Virus (HIV),

said method comprising administering to a patient: a) nitroglycerin, b) nitroprusside, c) an NO-generating derivative of a) or b), or d) a physiologically acceptable salt of a)-c).

10. The method claim 9 wherein said disorder is infection with HIV.

11. The method claim 9 wherein said disorder is hypoxia or ischemia.

12. The method of claim 9, claim 10 or claim 11 comprising administering nitroglycerin or a physiologically acceptable salt thereof to said patient.

13. The method of claim 9, claim 10 or claim 11 comprising administering nitroprusside or a physiologically acceptable salt thereof to said patient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc